Compare EPAC & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EPAC | MLTX |
|---|---|---|
| Founded | 1910 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 972.7M |
| IPO Year | N/A | N/A |
| Metric | EPAC | MLTX |
|---|---|---|
| Price | $40.74 | $14.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $50.50 | $36.33 |
| AVG Volume (30 Days) | 347.4K | ★ 1.9M |
| Earning Date | 12-17-2025 | 11-05-2025 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | ★ 8.66 | N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | ★ $616,899,000.00 | N/A |
| Revenue This Year | $6.18 | N/A |
| Revenue Next Year | $5.58 | N/A |
| P/E Ratio | $23.82 | ★ N/A |
| Revenue Growth | ★ 4.65 | N/A |
| 52 Week Low | $36.51 | $5.95 |
| 52 Week High | $49.40 | $62.75 |
| Indicator | EPAC | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 65.71 | 56.43 |
| Support Level | $36.80 | $13.87 |
| Resistance Level | $37.86 | $15.56 |
| Average True Range (ATR) | 1.01 | 0.78 |
| MACD | 0.46 | 0.31 |
| Stochastic Oscillator | 83.04 | 80.65 |
Enerpac Tool Group Corp provides high-precision hydraulic and mechanical tools, controlled-force products, and heavy lifting solutions. Operating mainly through its Industrial Tools & Services (IT&S) segment, the company designs, manufactures, and distributes branded tools, and offers maintenance, bolting, machining, joint integrity, and equipment rental services across industries such as oil & gas, manufacturing, power generation, and infrastructure. Its key products include hydraulic cylinders, pumps, torque wrenches, and bolt tensioners under the brands ENERPAC and HYDRATIGHT. The company serves customers internationally, with operations in the USA, Australia, Brazil, Germany, Saudi Arabia, the United Kingdom, and other countries, deriving the majority of its revenue from the USA.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.